X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
TFF VORI (voriconazole) is a next-generation, direct-to-lung, inhaled dry powder formulation of voriconazole for the treatment of invasive pulmonary aspergillosis & allergic bronchopulmonary aspergillosis.
Lead Product(s): Voriconazole
Therapeutic Area: Infections and Infectious Diseases Product Name: TFF VORI
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2024
Details:
TFF VORI (voriconazole inhalation powder) is a next-generation, direct-to-lung, inhaled dry powder formulation of voriconazole in development for the treatment and prevention of invasive pulmonary aspergillosis (IPA), a severe fungal pulmonary disease.
Lead Product(s): Voriconazole
Therapeutic Area: Infections and Infectious Diseases Product Name: TFF Vori
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 31, 2023
Details:
Voriconazole is a triazole antifungal agent. The primary mode of action of voriconazole is the inhibition of fungal cytochrome P-450-mediated 14 alpha-lanosterol demethylation, an essential step in fungal ergosterol biosynthesis.
Lead Product(s): Voriconazole
Therapeutic Area: Infections and Infectious Diseases Product Name: Vfend-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 02, 2023
Details:
TFF Pharmaceuticals intends to use the net proceeds from the offering for clinical trials, research and development, working capital and general corporate purposes.
Lead Product(s): Voriconazole
Therapeutic Area: Infections and Infectious Diseases Product Name: TFF VORI
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: JonesTrading Institutional Services
Deal Size: $12.3 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 29, 2022
Details:
TFF VORI (voriconazole) is a next-generation, direct-to-lung, inhaled dry powder formulation of voriconazole for the treatment and prevention of Invasive Pulmonary Aspergillosis (IPA).
Lead Product(s): Voriconazole
Therapeutic Area: Infections and Infectious Diseases Product Name: TFF VORI
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 01, 2022
Details:
TFF VORI (voriconazole) is a next-generation, direct-to-lung, inhaled dry powder formulation of voriconazole for the treatment and prevention of Invasive Pulmonary Aspergillosis (IPA).
Lead Product(s): Voriconazole
Therapeutic Area: Infections and Infectious Diseases Product Name: TFF VORI
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 01, 2022
Details:
TFF VORI is a next-generation, direct-to-lung, inhaled dry powder formulation of voriconazole for the treatment and prevention of Invasive Pulmonary Aspergillosis (IPA).
Lead Product(s): Voriconazole
Therapeutic Area: Infections and Infectious Diseases Product Name: TFF VORI
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2022
Details:
The Phase 1 clinical trial of Voriconazole Inhalation Powder for the treatment of invasive pulmonary aspergillosis (IPA) has been successfully completed and comprehensive safety and pharmacokinetic data is now available following delivery of the clinical study report.
Lead Product(s): Voriconazole
Therapeutic Area: Infections and Infectious Diseases Product Name: TFF VORI
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 04, 2021
Details:
Dosing of the Voriconazole Inhalation Powder resulted in plasma levels greater than drug levels achieved in published reports for dose levels that were efficacious in IPA patients.
Lead Product(s): Voriconazole
Therapeutic Area: Infections and Infectious Diseases Product Name: TFF VORI
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2020
Details:
Voriconazole Inhalation Powder is a next-generation, direct-to-lung, inhaled dry powder version of Voriconazole, generally considered to be the most effective antifungal drug for treating Invasive Pulmonary Aspergillosis (IPA).
Lead Product(s): Voriconazole
Therapeutic Area: Infections and Infectious Diseases Product Name: TFF VORI
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 30, 2020
Details:
Successfully completes single ascending dose phase of first clinical study in healthy subjects for a direct-to-lung, Thin Film Freezing (TFF) dry-powder formulation.
Lead Product(s): Voriconazole
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 19, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
